2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

Abstract Number: 1852

Validating Patient Reported Outcomes in Older Veterans with Chronic Back Pain
Abstract Number: 370

Validation of 2016 ACR/EULAR Classification Criteria of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis in Japanese Patients
Abstract Number: 2950

Validation of a Definition for Flare in Patients with Established Gout
Abstract Number: 1870

Validation of an Electronic Version of the Michigan Body Map
Abstract Number: 2858

Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy
Abstract Number: 2631

Validation of Clinically Relevant Improvement in Children and Adolescents with cSLE
Abstract Number: 2958

Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus
Abstract Number: 1494

Validation of New Criteria in “The Guidance for Diagnosis of Sjögren’s Syndrome in Pediatric Patients”
Abstract Number: 2548

Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Abstract Number: 248

Validation of Objective Quantification System for Disease Progression in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 586

Validation of Online Calibration Modules for the Spondyloarthritis Research Consortium of Canada MRI Scores Based on Real-Time Experiential Learning
Abstract Number: 1604

Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Abstract Number: 1508

Validation of Self-Reported Inflammatory Back Pain Score Compared to Rheumatology Consultation in University Students
Abstract Number: 1765

Validation of the ACR EULAR Provisional 2017 Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Patients with ANCA Associated Vasculitis
Abstract Number: 1360

Validation of the Health Assessment Questionnaire-Upper Extremity (HAQUP) in Patients with Rheumatoid Arthritis
Abstract Number: 94

Validity Evidence for an Objective Structured Clinical Examination Station to Assess Knee Arthrocentesis Skill
Abstract Number: 2039

Validity of the Wpai-SHP in Psoriatic Arthritis and Estimation of the Minimally Important Difference
Abstract Number: 464

Value of Matrix Metalloproteinase-3 Regarding Prediction for Joint Destruction at 1 Year Is Different between Sexes in Patients with Rheumatoid Arthritis
Abstract Number: 701

Variability in ICAP (International Consensus on ANA Patterns) Pattern Reporting in Testing for Antinuclear Antibodies (ANA) By Indirect Immunofluorescence Assay (IFA)
Abstract Number: 700

Variability in Method of Testing for Antinuclear Antibodies (ANA): A Survey of Participants in the College of American Pathologist’s (CAP) Proficiency Testing Program
Abstract Number: 1058

Variation in DMARD Therapy Following Methotrexate Failure for Newly-Identified Rheumatoid Arthritis in a National Veterans Health Administration Cohort
Abstract Number: 929

Variation in SLE-Related Pain – a Seven Year Follow-up Study
Abstract Number: 472

Viral Hepatitis Influences Patient Reported Outcomes Measures in Rheumatoid Arthritis
Abstract Number: 2692

Vitamin D Deficiency in Systemic Sclerosis Patients: Relations with Multiple Clinical Parameters and Standard Treatment
Abstract Number: 666

Vitamin D Deficiency Is Associated with Increased Serum Cholesterol Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1739

Vδ1, Vδ2, and Other γδT Cells in Blood and Synovium of Rheumatoid Arthritis and Other Autoimmune Arthritides

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].